LEP and myelodysplastic syndrome: Using follow-up data, we identified that a LEP promoter methylation cutoff of 51.03% in either peripheral blood granulocytes or bone marrow MNCs was able to stratify MDS patients with stable disease from those with progressive disease already at the time of diagnosis.